Production (Stage)
Interpace Biosciences, Inc.
IDXG
$0.80
$0.022.56%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -6.50% | 0.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -6.50% | 0.17% | |||
| Cost of Revenue | 21.95% | -29.02% | |||
| Gross Profit | -17.35% | 18.80% | |||
| SG&A Expenses | -5.10% | 4.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.78% | -11.03% | |||
| Operating Income | -40.46% | 61.26% | |||
| Income Before Tax | -38.21% | 109.96% | |||
| Income Tax Expenses | 325.00% | -300.00% | |||
| Earnings from Continuing Operations | -39.01% | 111.16% | |||
| Earnings from Discontinued Operations | -768.75% | 119.51% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.05% | 125.94% | |||
| EBIT | -40.46% | 61.26% | |||
| EBITDA | -39.25% | 59.07% | |||
| EPS Basic | -32.35% | 89.02% | |||
| Normalized Basic EPS | -38.37% | 109.26% | |||
| EPS Diluted | 15.43% | -83.33% | |||
| Normalized Diluted EPS | 11.11% | -81.35% | |||
| Average Basic Shares Outstanding | 0.27% | 0.34% | |||
| Average Diluted Shares Outstanding | -44.28% | 1,024.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||